Strategic expansion Target mid to large biotech and pharma companies exploring precision oncology solutions, leveraging TOMA OS-Seq technology for rapid, targeted sequencing that complements existing NGS platforms to accelerate clinical decision support.

Clinical impact Highlight evidence of improved progression free survival from independent studies to position TOMA as a value driver for oncologists and cancer centers investing in genomics-driven treatment optimization.

Integrated workflow Promote COMPASS Tumor Profiling System as a turnkey workflow from tumor sample to clinical reporting to reduce lab bottlenecks and improve time-to-result for customers with high-volume sequencing needs.

Funding readiness Leverage recent Series C funding and university-backed credibility to approach academic medical centers and translational research groups seeking innovative genomic solutions and validated tools.

Sustainability & scale Emphasize compatibility with existing NGS platforms and scalable reagent kits, offering a cost-efficient path for labs to upgrade capabilities without large capital expenditures.